Archives of Gynecology and Obstetrics

, Volume 292, Issue 4, pp 891–897 | Cite as

Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer

  • Li-ying Zhang
  • Pei-ling Li
  • Tian-zhen Wang
  • Xin-chen ZhangEmail author
Gynecologic Oncology



DNA methylation is an important epigenetic modification that is frequently altered in cancer. Recent reports showed that the level of 5-hydroxymethylcytosine (5-hmC) was altered in various types of cancers. The influence of DNA methylation in epithelial ovarian cancer (EOC) is not fully understood. Therefore, the aim of the present study was to investigate factors involved in DNA demethylation in EOC compared with normal ovarian tissues.


We examined the expression of 5-hmC, 5-mC, and TET2 by immunohistochemistry in 130 cases of EOC and 40 cases of normal ovarian tissues. We assessed the prognostic values of 5-hmC, 5-mC, and TET2 in clinical outcome of EOC.


We discovered a significant decrease in 5-hmC and TET2 expression in EOC compared with normal ovarian tissues. In contrast, there was a significant increase in 5-mC expression in EOC compared with normal ovarian tissues. The expression of 5-hmC, 5-mC, and TET2 correlated with pathologic stage, tumor grading, lymph node metastasis, and vascular thrombosis. Furthermore, decreased level of 5-hmC predicts poor prognosis of EOC patients. The expression of 5-hmC was an independent prognostic factor for overall survival of EOC patients.


The data suggest that loss of 5-hmC is an epigenetic event of EOC, and the expression of 5-hmC could serve as a prognostic factor for EOC.


5-hydoxymethylcytosine DNA methylation Ten-eleven translocation 2 Biological markers Epithelial ovarian cancer Survival 


Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

Ethical approval was given by the medical ethics committee of Second Affiliated Hospital of Harbin Medical University with the reference number 2014-yan-037.


  1. 1.
    Arikan SK, Kasap B, Yetimalar H, Yildiz A, Sakarya DK, Tatar S (2014) Impact of Prognostic Factors on Survival Rates in Patients with Ovarian Carcinoma. Asian Pac J Cancer Prev 15:6087–6094CrossRefPubMedGoogle Scholar
  2. 2.
    Rai Bhavana, Bansal Anshuma, Patel Firuza Darius, Sharma Suresh Chander (2014) Radiotherapy for ovarian cancers-redefining the role. Asian Pac J Cancer Prev 15:4759–4763CrossRefPubMedGoogle Scholar
  3. 3.
    Moszynski R, Szubert S, Szpurek D, Michalak S, Krygowska J, Sajdak S (2013) Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors. Arch Gynecol Obstet 288(6):1377–1383PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    He SY, Shen HW, Xu L, Li XL, Yao SZ (2012) Successful management of mucinous ovarian cancer by conservative surgery in week 6 of pregnancy: case report and literature review. Arch Gynecol Obstet 286(4):989–993PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Bell DA (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18:19–32CrossRefGoogle Scholar
  6. 6.
    Conteduca V, Kopf B, Burgio SL, Bianchi E, Amadori D, De Giorgi U (2014) The emerging role of anti-angiogenic therapy in ovarian cancer (Review). Int J ncol 44:1417–1424Google Scholar
  7. 7.
    YiChen Wu, Ling ZhiQiang (2014) The role of TET family proteins and 5-hydroxymethylcytosine in human tumors. Histol Histopathol 29:991–997Google Scholar
  8. 8.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRefPubMedGoogle Scholar
  9. 9.
    Berdasco M, Esteller M (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19:698–711CrossRefPubMedGoogle Scholar
  10. 10.
    Jones PA, Liang G (2009) Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 10:805–811PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27–36PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Kriaucionis S, Heintz N (2009) The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324:929–930PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Münzel M, Globisch D, Carell T (2011) 5-Hydroxymethylcytosine, the sixth base of the genome. Angew Chem Int Ed Engl 50:6460–6468CrossRefPubMedGoogle Scholar
  15. 15.
    Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Münzel M, Müller M, Pfaffeneder T, Hackner B, Feiden W, Schüller U, Carell T, Kretzschmar HA (2012) Low values of 5-hydroxymethylcytosine (5hmC), the ‘sixth base’, are associated with anaplasia in human brain tumors. Int J Cancer 131:1577–1590CrossRefPubMedGoogle Scholar
  16. 16.
    Pfeifer GP, Kadam S, Jin SG (2013) 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 6:10PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S (2011) Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2:627–637PubMedCentralPubMedGoogle Scholar
  18. 18.
    Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159CrossRefPubMedGoogle Scholar
  19. 19.
    Iyer LM, Thiliani M, Rao A, Aravind L (2009) Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8:1698–1710PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y (2013) Tumor development is associated with decrease of TET gene expression and 5-methlcytosine hydroxylation. Oncogene 32:663–669PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, Barbera AJ, Zheng L, Zhang H, Huang S, Min J, Nicholson T, Chen T, Xu G, Shi Y, Zhang K, Shi YG (2011) Genome-wide regulation of 5 hmC, 5 mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 42:451–464PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:1135–1146PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Gambichler T, Sand M, Skrygan M (2013) Loss of 5- hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res 23:218–220CrossRefPubMedGoogle Scholar
  25. 25.
    Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, Suzuki M, Sato Y (2013) In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci 104:1705–1710CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Li-ying Zhang
    • 1
  • Pei-ling Li
    • 1
  • Tian-zhen Wang
    • 2
  • Xin-chen Zhang
    • 3
    Email author
  1. 1.Department of Obstetrics and GynaecologySecond Affiliated Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Department of PathologyHarbin Medical UniversityHarbinChina
  3. 3.Department of General SurgeryThe Second Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations